<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353896</url>
  </required_header>
  <id_info>
    <org_study_id>6B-15-1</org_study_id>
    <secondary_id>NCI-2017-02074</secondary_id>
    <secondary_id>EF-OLIGO-15</secondary_id>
    <secondary_id>6B-15-1</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT03353896</nct_id>
  </id_info>
  <brief_title>NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma</brief_title>
  <official_title>Pilot Trial of NovoTTF -200A (TTFields) in Patients With Newly Diagnosed High Risk Oligodendrogliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the side effects of NovoTTF-200A device in treating&#xD;
      patients with newly diagnosed high risk oligodendroglioma. NovoTTF-200A device is a portable&#xD;
      battery operated device which produces tumor treating (TT)Fields in the body by means of&#xD;
      surface electrodes placed on the skin. TTFields are very low intensity, intermediate&#xD;
      frequency electric fields that may slow the growth of tumor cells in patients with high risk&#xD;
      oligodendroglioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the safety and tolerability of the TTFields treatment in patients with newly&#xD;
      diagnosed high risk oligodendroglioma following standard of care treatment.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the proportion of patients who tolerated 75% of treatment goal at months 6,&#xD;
      12, 24.&#xD;
&#xD;
      II. To estimate the progression free survival time. III. To assess quality of life. IV. To&#xD;
      assess whether or not there is a correlation between genomics and the efficacy of the&#xD;
      TTFields treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over&#xD;
      18 hours daily (QD). Treatment continues for up to 24 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 2 months and then monthly&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient accrual&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Actual">December 8, 2020</completion_date>
  <primary_completion_date type="Actual">December 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of the NovoTTFields treatment in patients with high risk oligodendroglioma</measure>
    <time_frame>Up to 2 months after treatment</time_frame>
    <description>Number of patients with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Oligoastrocytoma</condition>
  <condition>Oligodendroglioma</condition>
  <arm_group>
    <arm_group_label>Treatment (medical device)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours QD. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wear novoTTF-200A</intervention_name>
    <description>Wear novoTTF-200A device</description>
    <arm_group_label>Treatment (medical device)</arm_group_label>
    <other_name>Medical Devices</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (medical device)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed oligodendroglioma (oligo) (low grade oligo, low grade mixed&#xD;
             oligoastrocytoma, anaplastic oligo, anaplastic mixed oligo) by histology and or&#xD;
             molecular classification&#xD;
&#xD;
          -  Surgically sub-total or unresectable tumors, i.e. in insula, including but not limited&#xD;
             to the insula and received standard of care (SOC) radiation&#xD;
&#xD;
          -  Historical pathological tissue evidence of high risk oligo (low grade oligo, low grade&#xD;
             mixed oligoastrocytoma, anaplastic oligo, anaplastic mixed oligo) by histology and or&#xD;
             molecular classification&#xD;
&#xD;
          -  1p and 19q deletion status known&#xD;
&#xD;
          -  IDH 1 &amp; 2 mutations status known&#xD;
&#xD;
          -  MGMT status known&#xD;
&#xD;
          -  Karnofsky equal or greater than 70&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Participants of childbearing age must use effective contraception&#xD;
&#xD;
               -  A female of child-bearing potential is any woman (regardless of sexual&#xD;
                  orientation, having undergone a tubal ligation, or remaining celibate by choice)&#xD;
                  who meets the following criteria:&#xD;
&#xD;
                    -  Has not undergone a hysterectomy or bilateral oophorectomy; or&#xD;
&#xD;
                    -  Has not been naturally postmenopausal for at least 12 consecutive months&#xD;
                       (i.e., has had menses at any time in the preceding 12 consecutive months)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Actively participating in another clinical treatment trial&#xD;
&#xD;
          -  Tumor progression after radiation&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Has implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator,&#xD;
             other implanted electronic devices in the brain&#xD;
&#xD;
          -  Documented clinically significant cardiac arrhythmias&#xD;
&#xD;
          -  Infra-tentorial tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

